- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07523750
Étude du cathéter VARIPULSE à ablation par champ pulsé (PFA) et du cathéter FARAWAVE PFA dans le traitement des participants atteints de fibrillation auriculaire persistante (PERSIGMA RCT)
Comparaison de la sécurité et de l'efficacité d'un cathéter PFA VARIPULSE™ par rapport au cathéter PFA FARAWAVE™ dans le traitement des participants atteints de fibrillation auriculaire persistante : Un essai contrôlé randomisé
The purpose of this study is to assess how safe VARIPULSE pulsed field ablation (PFA) catheter is and how well it works compared to food and drug administration (FDA) approved FARAWAVE PFA catheter in participants with symptomatic persistent atrial fibrillation (PsAF; continuous irregular, rapid heartbeat that lasts over 7 days and doesn't stop on its own).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jesal Parekh
- Numéro de téléphone: 1 858 2108727
- E-mail: jparekh@its.jnj.com
Sauvegarde des contacts de l'étude
- Nom: Josiah M Gillespie
- Numéro de téléphone: 14059240777
- E-mail: jgille12@its.jnj.com
Lieux d'étude
-
-
Arkansas
-
Jonesboro, Arkansas, États-Unis, 72401
- Recrutement
- Arrhythmia Research Group
-
-
California
-
Fountain Valley, California, États-Unis, 92708
- Recrutement
- OC Medical Center
-
Ventura, California, États-Unis, 93003
- Recrutement
- Community Memorial Hospital
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32204
- Recrutement
- St. Vincents Medical Center
-
Miami, Florida, États-Unis, 33133
- Recrutement
- HCA Florida Mercy Hospital
-
Naples, Florida, États-Unis, 34102
- Recrutement
- NCH Healthcare
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30342
- Recrutement
- Emory Saint Joseph's Hospital
-
Savannah, Georgia, États-Unis, 31404
- Recrutement
- Memorial Health University Medical Center
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40503
- Recrutement
- Baptist Health Lexington
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Massachusetts General Hospital
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Beth Israel Deaconess Medical Center
-
-
Michigan
-
Ypsilanti, Michigan, États-Unis, 48197
- Recrutement
- Trinity Health Michigan Heart - Ann Arbor Campus
-
-
New Jersey
-
New Brunswick, New Jersey, États-Unis, 08901
- Recrutement
- Rutgers Robert Wood Johnson Medical School
-
-
New York
-
New York, New York, États-Unis, 10075
- Recrutement
- Lenox Hill Hospital
-
Rochester, New York, États-Unis, 14621
- Recrutement
- Rochester General Hospital
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center
-
-
North Carolina
-
Raleigh, North Carolina, États-Unis, 27610
- Recrutement
- WakeMed Hospital
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- Recrutement
- Texas Cardiac Arrhythmia Research Foundation
-
Plano, Texas, États-Unis, 75093
- Recrutement
- Baylor Research Institute
-
-
Utah
-
Murray, Utah, États-Unis, 84107
- Recrutement
- Intermountain Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
- Participant has been diagnosed with symptomatic persistent atrial fibrillation (PsAF), which is defined as continuous atrial fibrillation (AF) sustained beyond 7 days and less than 365 days in duration documented by: i. A physician's note documenting diagnosis of symptomatic PsAF as defined above and ii. Two electrocardiograms showing continuous AF, with electrocardiogram taken at least 7 days apart (electrocardiograms cannot be greater than [>] 365 days prior to enrollment) or iii. A 24-hour arrhythmia monitor documenting continuous AF within the last 365 days
- Participant is aged 18 - 80 years at the time of informed consent
- Participant is willing and capable of providing informed consent
- Participant is able and willing to comply with all pre-, post- and follow-up testing and requirements
Exclusion criteria:
- Participant has continuous AF > 365 days (longstanding persistent AF)
- Participant has AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, untreated documented obstructive sleep apnea, acute alcohol toxicity, etc.)
- Participant has had previous surgical or catheter ablation for AF
- Participant is known to require ablation outside the left atrium (LA), superior vena cava (SVC), and the cavotricuspid isthmus (CTI) region (for example, atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, ventricular tachycardia and Wolff-Parkinson-White)
- Participant has severe dilatation of the LA (LAD > 50 millimeters [mm]) of the antero-posterior diameter confirmed by imaging performed within 180 days prior to enrollment
- Participant has LA thrombus confirmed by imaging within 48 hours prior to the procedure
- Participant has severely compromised Left Ventricular Ejection Fraction (LVEF less than [<] 40%) confirmed by imaging performed within 180 days prior to enrollment
- Participant has uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
- Participant has a history of blood clotting, bleeding abnormalities or contraindication to anticoagulation (for example, heparin)
- Participant has had a thromboembolic event (including TIA) within the past 180 days prior to enrollment
- Participant has had a percutaneous coronary intervention or acute MI within past 60 days prior to enrollment
- Participant has had coronary artery bypass grafting (CABG) surgery within the past 180 days prior to enrollment
- Participant has had valvular cardiac surgical/percutaneous procedure (for example, ventriculotomy, atriotomy, valve repair or replacement and presence of a prosthetic valve)
- Participant has unstable angina within past 6 months prior to enrollment
- Participant has anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 365 days post-procedure
- Participant has significant pulmonary disease (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- Participant has a significant congenital anomaly (for example, atrial septal defects [ASDs]) including repaired defects or medical problems that in the opinion of the Investigator would preclude enrollment in this study
- Participant has an existing diagnosis of pulmonary vein stenosis (PVS)
- Participant has a pre-existing hemi-diaphragmatic paralysis
- Participant has an acute illness, active systemic infection, or sepsis
- Participant has an intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
- Participant has severe mitral regurgitation (regurgitant volume greater than or equal to [>=] 60 milliliters [mL]/beat, regurgitant fraction >= 50 percent [%], and/or effective regurgitant orifice area >= 0.40 square centimeter [cm^2])
- Participant has an implanted metal cardiac device, including MitraClip and left atrial appendage occlusion (LAAO) devices (for example, WATCHMAN, Amulet, etcetra.) and/or a double-coiled implantable cardioverter-defibrillators (ICD), (this exclusion does not include coronary stents, implanted pacemakers, single-coiled ICD and implantable loop recorders [ILR])
- Participant has a condition that precludes vascular access (such as inferior vena cava [IVC] filter)
- Participant is currently enrolled in an investigational study evaluating another device or drug
- Participant is pregnant, lactating, or is of child-bearing potential and plans on trying to become pregnant during the course of the clinical investigation
- Participant has a life expectancy less than 365 days
For magnetic resonance imaging (MRI) subset:
- Contraindication to use of contrast agents for MRI such as advanced renal disease etcetera
- Presence of iron-containing metal fragments in the body that renders the participant contraindicated for an MRI
- Unresolved pre-existing neurological deficit
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: VARIPULSE Pulsed Field Ablation (PFA) Catheter
Participants with persistent atrial fibrillation (PsAF) undergoing catheter ablation will undergo the ablation procedure with VARIPULSE catheter, and will be followed for up to 12 months post procedure. Eligible participants may enter an magnetic resonance imaging (MRI) subset and undergo MRI assessments at baseline and post-ablation procedure. |
Pulsed Field Ablation using the VARIPULSE catheter. |
|
Comparateur actif: FARAWAVE PFA Catheter
Participants with PsAF undergoing catheter ablation will undergo the ablation procedure with FARAWAVE catheter, and will be followed for up to 12 months post procedure. Eligible participants may enter an MRI subset and undergo MRI assessments at baseline and post-ablation procedure. |
Pulsed field ablation using the FARAWAVE catheter. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Occurrence of Early Onset Primary Adverse Events (PAEs)
Délai: Up to 7 days post-index procedure
|
PAEs that include early onset AEs such as esophageal perforating complications, phrenic nerve paralysis (PNP; permanent), cardiac tamponade/perforation, pulmonary vein stenosis (PVS), death (device or procedure related), stroke/ cerebrovascular accident (CVA), major vascular access, complication/bleeding, thromboembolism, myocardial infarction (MI), transient ischemic attack (TIA), pericarditis, pulmonary edema (respiratory insufficiency), heart block, and vagal nerve injury/ gastroparesis. |
Up to 7 days post-index procedure
|
|
Time to Occurrence of Documented (Symptomatic and Asymptomatic) Atrial Tachyarrhythmia Episodes
Délai: Day 61 and onward
|
Time to occurrence of documented (symptomatic and asymptomatic) atrial tachyarrhythmia (atrial fibrillation [AF], atrial tachycardia [AT] or atrial flutter [AFL] of unknown origin) episodes based on electrocardiographic data (12-Lead Electrocardiogram (ECG) or greater than equal to (>=) 30 seconds on sponsor provided Cardiac Event Monitor (CEM) or Patch arrhythmia monitor) during the effectiveness evaluation period or acute procedural failure, repeat ablation failure, surgical treatment for AF/AT/AFL, non-study catheter (NSC) failure, antiarrhythmic drug (AAD) failure and any direct current cardioversion (DCCV) procedure. |
Day 61 and onward
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Quality of life, As Measured by the Total Atrial Fibrillation Effect on Quality-of-Life (AFEQT) Score
Délai: Baseline and at 6 months post procedure
|
The AFEQT uses a questionnaire to evaluate symptoms, daily activities and treatment concerns participants have related to atrial fibrillation. An overall AFEQT score ranges from 0 to 100. A score of 0 corresponds to complete disability (or responding "extremely" difficult to all questions answered), while a score of 100 corresponds to no disability (or responding "not at all" limited, difficult or bothersome to all questions answered). A positive change in score corresponds to improvement in AF symptoms. |
Baseline and at 6 months post procedure
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- BWI202516
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of Johnson & Johnson MedTech is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .